MAP0001 for the Treatment of Diabetes
MAP0001 demonstrates our ability to apply our proprietary technologies to deliver biologically-active proteins and peptides to the lung. Without the need for excipients or other additives, we design and incorporate our protein formulations to be stored for months at room temperature, and to provide multiple doses of medicine to be delivered accurately without the need for invasive needle injections. MAP0001 is a proprietary formulation of insulin for the potential treatment of Type 1 and Type 2 diabetes via pulmonary delivery using our TempoŽ inhaler. In a Phase 1a clinical trial, MAP0001 was shown to be biologically active and achieved maximum therapeutic blood levels as quickly as subcutaneous insulin injection.
[to top]